Central nervous system directed therapy in acute lymphoblastic leukaemia (Q40558249)

21 September 2017

1 reference

title

Central nervous system directed therapy in acute lymphoblastic leukaemia (English)

1 reference

21 September 2017

1 reference

Chessells JM

1

1 reference

21 September 2017

1 June 1994

1 reference

Best Practice and Research: Clinical Haematology

21 September 2017

1 reference

21 September 2017

7

1 reference

21 September 2017

349-363

1 reference

21 September 2017

2

1 reference

High-dose methotrexate: a critical reappraisal

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Cytarabine and neurologic toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Remission induction of meningeal leukemia with high-dose intravenous methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Treatment of central nervous system leukemia with intrathecal cytosine arabinoside

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Treatment of acute lymphoblastic leukaemia in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: Prolonged remission with the ommaya reservoir

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Neurotoxicity and Elevated Cerebrospinal-Fluid Methotrexate Concentration in Meningeal Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Influence of age, sex, and concurrent intrathecal methotrexate therapy on intellectual function after cranial irradiation during childhood: a report from the Children's Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

How much is too much? Folinic acid rescue dose in children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Neurotoxicity in lymphoblastic leukaemia: comparison of oral and intramuscular methotrexate and two doses of radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Progression of methotrexate-induced leukoencephalopathy in children with leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Cognitive effects of cranial irradiation in leukaemia: a survey and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

The increasing incidence of central nervous system leukemia in children. (Children's Cancer Study Group A).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Cancer in Relatives of Children with Central-Nervous-System Neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Comparison of intermediate-dose methotrexate with cranial irradiation for the post-induction treatment of acute lymphocytic leukemia in children

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

The importance of an isolated central nervous system relapse in children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

B cell acute lymphocytic leukemia in adults. Clinical, morphologic, and immunologic findings

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Long-term control of central nervous system leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

'MACHO' chemotherapy for stage IV B cell lymphoma and B cell acute lymphoblastic leukaemia of childhood. United Kingdom Children's Cancer Study Group (UKCCSG)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

1 reference

7 January 2021

Combination chemotherapy and radiotherapy for acute lymphocytic leukemia in adults: Results of CALGB protocol 7113

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Prevention of central nervous system leukemia by irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Are cognitive and educational development affected by age at which prophylactic therapy is given in acute lymphoblastic leukaemia?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

CNS prophylaxis in acute lymphoblastic leukemia: comparison of two methods a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Central Nervous System Disease in Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Results of Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Treatment of meningeal relapse in childhood acute lymphoblastic leukemia. I. Results of craniospinal irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Identification of leukemic cells in the cerebrospinal fluid from children with acute lymphoblastic leukemia: advances and dilemmas.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Acute lymphoblastic leukaemia under 2 years

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Precocious or early puberty and growth failure in girls treated for acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Central nervous system (CNS) prophylaxis in children with low risk acute lymphoblastic leukemia (ALL).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Treatment of meningeal relapse in childhood acute lymphoblastic leukemia: II. A prospective study of intellectual loss specific to CNS relapse and therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Delayed central nervous system (CNS) radiation in childhood CNS acute lymphoblastic leukemia. Results of a pilot trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Medical Research Council leukaemia trial--UKALL V: an attempt to reduce the immunosuppressive effects of therapy in childhood acute lymphoblastic leukemia. Report to the Council by the Working Party on Leukaemia in Childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Meningosis prophylaxis with intrathecal198Au-colloid and methotrexate in childhood acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Intermediate dose methotrexate (IDM) in childhood acute lymphocytic leukemia in Norway. Preliminary results of a national treatment program

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Second neoplasms after acute lymphoblastic leukemia in childhood.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Presymptomatic central nervous system therapy in previously untreated childhood acute lymphoblastic leukaemia: comparison of 1800 rad and 2400 rad. A report for Children's Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Radiotherapy of the central nervous system in acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Long-term evaluation of a CNS prophylaxis trial--treatment comparisons and outcome after CNS relapse in childhood ALL: a report from the Childrens Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

A pilot study of monoclonal antibody targeted radiotherapy in the treatment of central nervous system leukaemia in children

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

The central nervous system in childhood leukemia: I. The arachnoid

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

High dose cytosine arabinoside in the initial treatment of adults with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Normal growth despite abnormalities of growthhormone secretion in children treated for acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Lymphomatous presentation of childhood acute lymphoblastic leukemia. A subgroup at high risk of early treatment failure

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Minimal neuropsychological sequelae following prophylactic treatment of the central nervous system in adult leukaemia and lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Factors in Pathogenesis of Central-nervous-system Leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Medical cost of curing childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

Treatment of overt meningeal leukaemia in children: results of second MRC meningeal leukaemia trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980207-0

7 January 2021

10.1016/S0950-3536(05)80207-0

Identifiers

DOI

1 reference

21 September 2017

1 reference

PubMed ID

7803906